Revance Therapeutics, Inc. - Common Stock
Own 1 of RVNC at $34.50 which is 0.06% of the portfolio.
|Range Today||$33.32 - $34.75|
|52 Week Range||$16.40 - $37.20|
Revance Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages on the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic, and therapeutic applications. It focuses on the development of daxibotulinumtoxinA, a botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Newark, CA.